Pd57-03 Clinical Characteristics of Secondary Bladder Cancer Developing After Low-/High-Dose-Rate Brachytherapy to Treat Localized Prostate Cancer

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy (PD57)1 May 2024PD57-03 CLINICAL CHARACTERISTICS OF SECONDARY BLADDER CANCER DEVELOPING AFTER LOW-/HIGH-DOSE-RATE BRACHYTHERAPY TO TREAT LOCALIZED PROSTATE CANCER Hirokazu Kagawa, Fumihiko Urabe, Keiichiro Miyajima, Kojiro Tashiro, Hirotaka Suzuki, Manabu Aoki, Shun Sato, Hiroyuki Takahashi, and Takahiro Kimura Hirokazu KagawaHirokazu Kagawa , Fumihiko UrabeFumihiko Urabe , Keiichiro MiyajimaKeiichiro Miyajima , Kojiro TashiroKojiro Tashiro , Hirotaka SuzukiHirotaka Suzuki , Manabu AokiManabu Aoki , Shun SatoShun Sato , Hiroyuki TakahashiHiroyuki Takahashi , and Takahiro KimuraTakahiro Kimura View All Author Informationhttps://doi.org/10.1097/01.JU.0001008808.16085.aa.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To explore correlations between the clinical attributes of secondary bladder cancer and brachytherapy, we retrospectively reviewed our institutional database on patients with localized prostate cancer who underwent low-dose-rate brachytherapy (LDR-BT) or high-dose-rate brachytherapy (HDR-BT) with or without external beam radiation therapy (EBRT) or radical prostatectomy (RP). METHODS: From October 2003 to December 2014, 2,551 patients with localized prostate cancer were treated at our institution. Of these, data on 2,163 were available (LDR-BT alone: n=953; LDR-TB with EBRT: n=181; HDR-BT with EBRT: n=283; RP without EBRT: n=746). The times of secondary bladder cancer development subsequent to radical treatment, and their clinical characteristics, were studied. RESULTS: During follow-up, 46 (2.1%) patients developed bladder cancer. The median follow-up period from radical treatment to the development of such cancer was 74.5 months (range 4–196 months). Of patients who received LDR-BT alone, LDR-BT with EBRT, HDR-BT with EBRT, and RP, 19 (2.0%), 7 (3.9%), 8 (2.8%), and 12 (1.6%) developed bladder cancer, respectively (Figure 1). Such patients were significantly older than others (p=0.009). Age-adjusted Cox's regression analyses indicated that brachytherapy did not significantly impact the incidence of secondary bladder cancer. However, the pathological characteristics of such cancer differed between patients treated via brachytherapy and RP without EBRT; invasive bladder cancer was more common in such patients. CONCLUSIONS: Brachytherapy did not increase the risk for secondary bladder cancer compared to non-irradiation therapy. However, secondary bladder cancer in patients after brachytherapy is more invasive than after non-radiation therapy; careful follow-up is essential to ensure early diagnosis and treatment, especially if the patients present with hematuria. Our findings provide patients and physicians with useful information on the risk for secondary bladder cancer after brachytherapy. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1209 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Hirokazu Kagawa More articles by this author Fumihiko Urabe More articles by this author Keiichiro Miyajima More articles by this author Kojiro Tashiro More articles by this author Hirotaka Suzuki More articles by this author Manabu Aoki More articles by this author Shun Sato More articles by this author Hiroyuki Takahashi More articles by this author Takahiro Kimura More articles by this author Expand All Advertisement PDF downloadLoading ...